PharmaMar announces the IDMC's response on the CORAIL trial using PM1183 (lurbinectedin)

press release

Madrid, August 11th, 2016 - PharmaMar (MSE:PHM) announces that it has received the approval from the Independent Data Monitoring Committee (IDMC) to continue with the pivotal CORAIL study of PM1183 (lurbinectedin) in patients with platinum-resistant ovarian cancer up to the recruitment of the 420 patients established in the protocol.
This decision is based on the futility analysis of the first 210 patients (50% of the total 420), in which the safety and efficacy of PM1183 in this indication were evaluated.
CORAIL is a randomized Phase III Trial to evaluate the efficacy of PM1183 in comparison with topotecan or pegylated lyposomal doxorubicin, standard treatment of care for this pathology, in 420 patients.....